[go: up one dir, main page]

DE60105025D1 - Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie - Google Patents

Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie

Info

Publication number
DE60105025D1
DE60105025D1 DE60105025T DE60105025T DE60105025D1 DE 60105025 D1 DE60105025 D1 DE 60105025D1 DE 60105025 T DE60105025 T DE 60105025T DE 60105025 T DE60105025 T DE 60105025T DE 60105025 D1 DE60105025 D1 DE 60105025D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compounds
treating chronic
bronchopneumonia
obstructive
obstructive bronchopneumonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60105025T
Other languages
English (en)
Other versions
DE60105025T2 (de
Inventor
Kam-Wah Thong
Anthony J Kettle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60105025D1 publication Critical patent/DE60105025D1/de
Application granted granted Critical
Publication of DE60105025T2 publication Critical patent/DE60105025T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60105025T 2000-05-12 2001-05-08 Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie Expired - Fee Related DE60105025T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0011358A GB2362101A (en) 2000-05-12 2000-05-12 Treatment of chronic obstructive pulmonary disease
GB0011358 2000-05-12
PCT/SE2001/001014 WO2001085146A1 (en) 2000-05-12 2001-05-08 Pharmaceutical compounds for treating copd

Publications (2)

Publication Number Publication Date
DE60105025D1 true DE60105025D1 (de) 2004-09-23
DE60105025T2 DE60105025T2 (de) 2005-08-18

Family

ID=9891383

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105025T Expired - Fee Related DE60105025T2 (de) 2000-05-12 2001-05-08 Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie

Country Status (10)

Country Link
US (1) US20040029871A1 (de)
EP (1) EP1294366B1 (de)
JP (1) JP2004509841A (de)
CN (1) CN1427718A (de)
AT (1) ATE273699T1 (de)
AU (1) AU2001260880A1 (de)
CA (1) CA2406512A1 (de)
DE (1) DE60105025T2 (de)
GB (1) GB2362101A (de)
WO (1) WO2001085146A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
CA2398642A1 (en) * 2000-01-31 2001-08-02 Yuhong Zhou Mucin synthesis inhibitors
SE0103766D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
MXPA03006549A (es) * 2003-07-22 2004-03-18 Univ Autonoma Metropolitana Uso de la dapsona como neuroprotector en el infarto cerebral.
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
CA2687715A1 (en) * 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
EP2671614A1 (de) * 2007-12-21 2013-12-11 University of Rochester Molekulare Ziele zur Behandlung von Entzündungen
US20130005822A1 (en) * 2010-03-15 2013-01-03 Rubin Bruce K Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US20110287468A1 (en) 2010-04-19 2011-11-24 General Atomics Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples
EP2654749B1 (de) * 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Verfahren zur behandlung von copd
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
EP2682119A1 (de) * 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatische N-heterocyclische Derivate zur Verwendung als Medizin
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
EP3654983B1 (de) * 2017-07-17 2023-08-30 Astrazeneca AB Mpo-inhibitoren zur verwendung in der medizin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.

Also Published As

Publication number Publication date
JP2004509841A (ja) 2004-04-02
WO2001085146A1 (en) 2001-11-15
ATE273699T1 (de) 2004-09-15
CA2406512A1 (en) 2001-11-15
EP1294366A1 (de) 2003-03-26
EP1294366B1 (de) 2004-08-18
CN1427718A (zh) 2003-07-02
US20040029871A1 (en) 2004-02-12
GB2362101A (en) 2001-11-14
AU2001260880A1 (en) 2001-11-20
GB0011358D0 (en) 2000-06-28
DE60105025T2 (de) 2005-08-18

Similar Documents

Publication Publication Date Title
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60239554D1 (de) Medizinische vorrichtung zur abgabe von pflastern
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
EP1556085A4 (de) Verbindungen zur behandlung von stoffwechselst rungen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE60130659D1 (de) Therapeutische verbindungen und verfahren
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE322898T1 (de) Inhibitoren von mycobakterien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee